SYNERGY(SZ:300636)2021-08-05 16:00Financial Performance - The company reported a significant increase in revenue for the first half of 2021, with total revenue reaching 500 million RMB, representing a 20% growth compared to the same period last year[20]. - The company achieved operating revenue of CNY 277.53 million, representing a 17.03% increase compared to the same period last year[26]. - Net profit attributable to shareholders was CNY 42.53 million, up 1.89% year-on-year[26]. - The company reported a significant increase in revenue, achieving a total of 500 million RMB for the first half of 2021, representing a 25% year-over-year growth[92]. - The company reported a net profit for the first half of 2021 of CNY 42,529,070.41, representing a slight increase of 1.9% from CNY 41,739,205.05 in the previous year[184]. Research and Development - The company plans to invest 100 million RMB in R&D for new drug development, focusing on innovative pharmaceutical products and enhancing its competitive edge in the market[20]. - Research and development investment reached CNY 14.64 million, accounting for 5.28% of the current operating revenue[34]. - The company continues to focus on R&D in various therapeutic areas, including anticoagulants and anti-diabetic medications[34]. - The company maintains a research and development investment ratio of 8%-9% of sales revenue, continuously enriching its product line and ensuring a stable order flow[43]. - The company is investing in R&D, with a budget increase of 15% for new technology development in 2021[92]. Market Expansion and Strategy - The company aims to expand its market presence in Southeast Asia, targeting a 10% increase in export revenue by the end of 2021[20]. - The management provided an optimistic outlook, projecting a revenue growth of 25% for the full year 2021, driven by new product launches and market expansion efforts[20]. - The company has identified potential acquisition targets in the biotechnology sector to enhance its product portfolio and market reach[20]. - Market expansion plans include entering two new provinces, aiming for a 10% market share in these regions by the end of 2022[92]. - The company is considering strategic acquisitions to enhance its product portfolio, with potential targets identified in the pharmaceutical sector[92]. Production and Capacity - A new production facility is expected to be operational by Q4 2021, which will increase production capacity by 30% and support the growing demand for its products[20]. - The company has a total of 12 synthesis workshops and over 500 reaction kettles, indicating strong production capacity[55]. - The first plant's renovation project has been completed, enhancing production capacity and accelerating the launch of new products[132]. Environmental Compliance - The company is committed to maintaining compliance with environmental regulations, with an investment of 5 million RMB in waste management systems to ensure sustainable operations[20]. - The company has established a comprehensive cGMP quality management system, which has been validated by successful inspections from multiple international regulatory authorities[52]. - The company has a wastewater treatment capacity of 1,500 tons per day, with additional evaporation facilities for further treatment[101]. - The company reported no environmental pollution incidents or administrative penalties during the reporting period[105]. Financial Management - The company will not distribute cash dividends for the year, opting to reinvest profits into business growth and development initiatives[20]. - The company has cumulatively invested ¥28,467.51 million of the raised funds, with ¥14,892.84 million invested during the reporting period[68]. - The company raised a total of RMB 360 million through the issuance of convertible bonds, with a net amount of RMB 354.19 million after deducting issuance costs[71]. - The company has not reported any changes in fundraising projects during the reporting period[75]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 8,855[146]. - Major shareholder Pang Zhengwei holds 18.18% of shares, totaling 37,434,998 shares, with 9,358,750 shares pledged[146]. - The company’s management increased their shareholdings during the reporting period, affecting the number of limited sale shares[138]. - The total shares held by the chairman and general manager, Pang Zhengwei, increased from 23,396,874 to 37,434,998 shares, reflecting a net increase of 14,038,124 shares[151]. Risks and Challenges - The company faced challenges such as rising raw material prices and tight export shipping capacity during the reporting period[34]. - The company faces risks related to national policies and industry regulations, which may impact drug production and competition[83]. - There is a risk associated with the renewal of major operating qualifications, as failure to obtain necessary licenses could halt production and sales[84]. - The company is exposed to exchange rate risks due to a high proportion of export revenue, primarily denominated in USD[90].